Literature DB >> 21512658

Feasibility and performance of novel software to quantify metabolically active volumes and 3D partial volume corrected SUV and metabolic volumetric products of spinal bone marrow metastases on 18F-FDG-PET/CT.

Drew A Torigian1, Rosa Fernandez Lopez, Sridevi Alapati, Geetha Bodapati, Frank Hofheinz, Joerg van den Hoff, Babak Saboury, Abass Alavi.   

Abstract

Our aim was to assess feasibility and performance of novel semi-automated image analysis software called ROVER to quantify metabolically active volume (MAV), maximum standardized uptake value-maximum (SUV(max)), 3D partial volume corrected mean SUV (cSUV(mean)), and 3D partial volume corrected mean MVP (cMVP(mean)) of spinal bone marrow metastases on fluorine-18 fluorodeoxyglucose-positron emission tomography/computerized tomography ((18)F-FDG-PET/CT). We retrospectively studied 16 subjects with 31 spinal metastases on FDG-PET/CT and MRI. Manual and ROVER determinations of lesional MAV and SUV(max), and repeated ROVER measurements of MAV, SUV(max), cSUV(mean) and cMVP(mean) were made. Bland-Altman and correlation analyses were performed to assess reproducibility and agreement. Our results showed that analyses of repeated ROVER measurements revealed MAV mean difference (D)=-0.03±0.53cc (95% CI(-0.22, 0.16)), lower limit of agreement (LLOA)=-1.07cc, and upper limit of agreement (ULOA)=1.01cc; SUV(max) D=0.00±0.00 with LOAs=0.00; cSUV(mean) D=-0.01±0.39 (95% CI(-0.15, 0.13)), LLOA=-0.76, and ULOA=0.75; cMVP(mean) D=-0.52±4.78cc (95% CI(-2.23, 1.23)), LLOA=-9.89cc, and ULOA=8.86cc. Comparisons between ROVER and manual measurements revealed volume D= -0.39±1.37cc (95% CI (-0.89, 0.11)), LLOA=-3.08cc, and ULOA=2.30cc; SUV(max) D=0.00±0.00 with LOAs=0.00. Mean percent increase in lesional SUV(mean) and MVP(mean) following partial volume correction using ROVER was 84.25±36.00% and 84.45±35.94% , respectively. In conclusion, it is feasible to estimate MAV, SUV(max), cSUV(mean), and cMVP(mean) of spinal bone marrow metastases from (18)F-FDG-PET/CT quickly and easily with good reproducibility via ROVER software. Partial volume correction is imperative, as uncorrected SUV(mean) and MVP(mean) are significantly underestimated, even for large lesions. This novel approach has great potential for practical, accurate, and precise combined structural-functional PET quantification of disease before and after therapeutic intervention.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21512658

Source DB:  PubMed          Journal:  Hell J Nucl Med        ISSN: 1790-5427            Impact factor:   1.102


  19 in total

1.  Dual time-point FDG PET/CT and FDG uptake and related enzymes in lymphadenopathies: preliminary results.

Authors:  Sofie Bæk Christlieb; Casper Nørgaard Strandholdt; Birgitte Brinkmann Olsen; Karen Juul Mylam; Thomas Stauffer Larsen; Anne Lerberg Nielsen; Max Rohde; Oke Gerke; Karen Ege Olsen; Michael Boe Møller; Bjarne Winther Kristensen; Niels Abildgaard; Abass Alavi; Poul Flemming Høilund-Carlsen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-22       Impact factor: 9.236

Review 2.  A review on segmentation of positron emission tomography images.

Authors:  Brent Foster; Ulas Bagci; Awais Mansoor; Ziyue Xu; Daniel J Mollura
Journal:  Comput Biol Med       Date:  2014-04-28       Impact factor: 4.589

3.  Pretreatment volumetric parameters of FDG-PET predict the survival after Yttrium-90 radio-embolization in metastatic liver disease.

Authors:  Siavash Mehdizadeh Seraj; Mahdi Zirakchian Zadeh; Thomas J Werner; Hongming Zhuang; Terence Gade; Abass Alavi; Stephen J Hunt
Journal:  Am J Nucl Med Mol Imaging       Date:  2019-10-15

4.  Correction for Partial Volume Effect Is a Must, Not a Luxury, to Fully Exploit the Potential of Quantitative PET Imaging in Clinical Oncology.

Authors:  Abass Alavi; Thomas J Werner; Poul Flemming Høilund-Carlsen; Habib Zaidi
Journal:  Mol Imaging Biol       Date:  2018-02       Impact factor: 3.488

Review 5.  Applications of PET-Computed Tomography-Magnetic Resonance in the Management of Benign Musculoskeletal Disorders.

Authors:  James S Yoder; Feliks Kogan; Garry E Gold
Journal:  PET Clin       Date:  2019-01

6.  The role of serial FDG PET for assessing therapeutic response in patients with cardiac sarcoidosis.

Authors:  Pei-Ing Lee; Gang Cheng; Abass Alavi
Journal:  J Nucl Cardiol       Date:  2016-11-03       Impact factor: 5.952

7.  FDG PET/CT in Crohn's disease: correlation of quantitative FDG PET/CT parameters with clinical and endoscopic surrogate markers of disease activity.

Authors:  Babak Saboury; Ali Salavati; Alex Brothers; Sandip Basu; Thomas C Kwee; Marnix G E H Lam; Roland Hustinx; Edouard Louis; Drew A Torigian; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-11-20       Impact factor: 9.236

8.  Application of partial volume effect correction and 4D PET in the quantification of FDG avid lung lesions.

Authors:  Ali Salavati; Samuel Borofsky; Teo K Boon-Keng; Sina Houshmand; Benjapa Khiewvan; Babak Saboury; Ion Codreanu; Drew A Torigian; Habib Zaidi; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2015-02       Impact factor: 3.488

Review 9.  Emerging optical and nuclear medicine imaging methods in rheumatoid arthritis.

Authors:  James M Mountz; Abass Alavi; John D Mountz
Journal:  Nat Rev Rheumatol       Date:  2012-09-25       Impact factor: 20.543

10.  Prognostic significance of 18F-sodium fluoride in newly diagnosed multiple myeloma patients.

Authors:  Mahdi Zirakchian Zadeh; Siavash Mehdizadeh Seraj; Brian Østergaard; Stephanie Mimms; William Y Raynor; Mahmoud Aly; Austin J Borja; Leila S Arani; Oke Gerke; Thomas J Werner; Hongming Zhuang; Mona-Elisabeth Revheim; Niels Abildgaard; Poul Flemming Høilund-Carlsen; Abass Alavi
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-08-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.